Market Cap 59.40M
Revenue (ttm) 0.00
Net Income (ttm) -24.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 616,441
Avg Vol 735,796
Day's Range N/A - N/A
Shares Out 24.44M
Stochastic %K 67%
Beta 1.61
Analysts Strong Sell
Price Target $11.67

Company Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phas...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 875 3192
Address:
101 Lindenwood Drive, Suite 225, Malvern, United States
Veni_Vidi_Vici
Veni_Vidi_Vici Nov. 14 at 6:32 PM
$ANVS https://www.sec.gov/ix?doc=/Archives/edgar/data/0001477845/000110465925110393/anvs-20250930x10q.htm
0 · Reply
kgw567
kgw567 Nov. 14 at 3:44 PM
$ANVS Anavex Life Sciences Corp. (NASDAQ:AVXL) experienced a catastrophic trading session on November 14, 2025, with shares plummeting approximately 50% in premarket trading following a significant regulatory setback in Europe. The dramatic sell-off was triggered by a negative trend vote from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) regarding the company’s Alzheimer’s disease drug candidate, blarcamesine.
0 · Reply
wgreystone
wgreystone Nov. 14 at 3:16 PM
$ANVS is the only hope for Alzheimer’s patients
0 · Reply
_HUNTERXHUNTER_
_HUNTERXHUNTER_ Nov. 14 at 3:06 PM
0 · Reply
BIOMILITIA
BIOMILITIA Nov. 14 at 3:04 PM
$ANVS 😈
0 · Reply
uphillclimb13
uphillclimb13 Nov. 14 at 2:16 PM
$ANVS AVXL Shares Slump Pre-Market After EMA Committee Fails To Recommend Approval For Alzheimer’s Drug Down 45% premarket
0 · Reply
Animalhouse123
Animalhouse123 Nov. 14 at 1:05 PM
$ANVS I am guessing this will be the Trifecta with SAVA, AVXL and this garbage…….
0 · Reply
NolAsrtormZ
NolAsrtormZ Nov. 14 at 1:00 PM
$ANVS soon $AVXL will be close in price
0 · Reply
Voykky
Voykky Nov. 14 at 12:38 PM
$ANVS And another one bites the dust. AVXL gone.
2 · Reply
Bull69Bear
Bull69Bear Nov. 14 at 12:37 PM
$ANVS My outlook for ADs readout next year is unchanged but I liked the recent updates.
1 · Reply
Latest News on ANVS
Annovis Appoints Mark Guerin as Chief Financial Officer

Sep 25, 2025, 7:30 AM EDT - 7 weeks ago

Annovis Appoints Mark Guerin as Chief Financial Officer


Annovis Completes Full Patent Transfer to Crystal Buntanetap

Aug 7, 2025, 8:00 AM EDT - 3 months ago

Annovis Completes Full Patent Transfer to Crystal Buntanetap


Annovis to Attend the AAIC 2025 with Four Poster Presentations

Jun 26, 2025, 8:00 AM EDT - 5 months ago

Annovis to Attend the AAIC 2025 with Four Poster Presentations


Annovis to Host Webinar and Live Q&A on June 24, 2025

Jun 5, 2025, 8:00 AM EDT - 5 months ago

Annovis to Host Webinar and Live Q&A on June 24, 2025


Annovis Bio Appoints Hui Liu as Director of Biostatistics

Apr 29, 2025, 8:00 AM EDT - 7 months ago

Annovis Bio Appoints Hui Liu as Director of Biostatistics


Annovis to Host Patients' Live Forum on February 27, 2025

Feb 19, 2025, 8:30 AM EST - 9 months ago

Annovis to Host Patients' Live Forum on February 27, 2025


Annovis Bio, Inc. Announces Proposed Public Offering

Jan 31, 2025, 8:14 PM EST - 10 months ago

Annovis Bio, Inc. Announces Proposed Public Offering


/C O R R E C T I O N -- Today's Marketplace/

Dec 4, 2024, 2:21 PM EST - 1 year ago

/C O R R E C T I O N -- Today's Marketplace/


Annovis stock more than doubled on Tuesday: what happened?

Jul 2, 2024, 4:13 PM EDT - 1 year ago

Annovis stock more than doubled on Tuesday: what happened?


Annovis Announces New Publication in a Peer-Reviewed Journal

May 21, 2024, 7:30 AM EDT - 1 year ago

Annovis Announces New Publication in a Peer-Reviewed Journal


Veni_Vidi_Vici
Veni_Vidi_Vici Nov. 14 at 6:32 PM
$ANVS https://www.sec.gov/ix?doc=/Archives/edgar/data/0001477845/000110465925110393/anvs-20250930x10q.htm
0 · Reply
kgw567
kgw567 Nov. 14 at 3:44 PM
$ANVS Anavex Life Sciences Corp. (NASDAQ:AVXL) experienced a catastrophic trading session on November 14, 2025, with shares plummeting approximately 50% in premarket trading following a significant regulatory setback in Europe. The dramatic sell-off was triggered by a negative trend vote from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) regarding the company’s Alzheimer’s disease drug candidate, blarcamesine.
0 · Reply
wgreystone
wgreystone Nov. 14 at 3:16 PM
$ANVS is the only hope for Alzheimer’s patients
0 · Reply
_HUNTERXHUNTER_
_HUNTERXHUNTER_ Nov. 14 at 3:06 PM
0 · Reply
BIOMILITIA
BIOMILITIA Nov. 14 at 3:04 PM
$ANVS 😈
0 · Reply
uphillclimb13
uphillclimb13 Nov. 14 at 2:16 PM
$ANVS AVXL Shares Slump Pre-Market After EMA Committee Fails To Recommend Approval For Alzheimer’s Drug Down 45% premarket
0 · Reply
Animalhouse123
Animalhouse123 Nov. 14 at 1:05 PM
$ANVS I am guessing this will be the Trifecta with SAVA, AVXL and this garbage…….
0 · Reply
NolAsrtormZ
NolAsrtormZ Nov. 14 at 1:00 PM
$ANVS soon $AVXL will be close in price
0 · Reply
Voykky
Voykky Nov. 14 at 12:38 PM
$ANVS And another one bites the dust. AVXL gone.
2 · Reply
Bull69Bear
Bull69Bear Nov. 14 at 12:37 PM
$ANVS My outlook for ADs readout next year is unchanged but I liked the recent updates.
1 · Reply
ForestFoxes
ForestFoxes Nov. 14 at 9:56 AM
$ANVS 📚8.6 🔦 👀 Insights ... anticipation of being bullied 😬 [This post overlaps with the topic of demographics hence could be labelled 📚7.2 🔍 ] https://stocktwits.com/ForestFoxes/message/635697974 📚7.1 🔍 has an image showing investors to losses exceeding -98%! Why then are some shareholders attacking other shareholders whose opinions have changed? Or, those such as myself who have seen the inside of the company and had hundreds of direct interacts with Dr. Maccecchini? Some of these attacks are very personal. Why? From the very beginning my interest was in helping Dr. Maccecchini get a supposedly efficacious drug to help patients. That's what she said, I believed her, and I wanted to help. Note in the first image that Dr. Maccecchini is asking for assistance in who to hire. She also tells me that the issue "isn't just the money". Why are people on this channel attacking me if Maria is saying things like "I owe you a lot and will do it this afternoon" ... unless people ONLY want to hear positive spin (lies)? Help me make sense of this situation without sharing your opinion about the science/data unless you also have been given access to data, know what the Scientific Advisory Board members think of Dr. Maccecchini's drug, and/or gone out to San Diego to meet one of the lead investigators to have one-on-one discussion. Why are some people saying that I've spent too much time on this? How much time would you spend on a project like this if it could save millions of patients from the horrors of dementia along with the pain it causes their family? And, if you found out that this drug isn't efficacious and that this company is hurting the industry how much time would you spend on it knowing that capital is being misdirected and that patients are being hurt? Note 📍: The fourth image relates to my meeting with distinguished professor, William Mobley, PhD. In the lower right-hand corner of that 4-panel image is a grey informational box which I hope readers who have suffered losses during the 2021 Class Period will concern taking immediate action given the approaching statue of limitations. Other Class Periods will undoubtedly come about, however it is the 2021 Class Period that is currently in jeopardy. #statnews #adamfeuerstein
0 · Reply
ForestFoxes
ForestFoxes Nov. 14 at 9:06 AM
$ANVS 📚8.5 🔦 👀 Insights ... Adam Feuerstein & Stat News. Observations: Many investors think that 👉 "The lawyers have told me to shut up ..." is an proof that Maria is too honest 🤷🏻‍♀️ʷᵗᶠ Many investors loved that Dr. Maccecchini went onto SeekingAlpha to chastise journalists. One mentioned that it was like "Maria gave them a spanking!" 🤦🏻‍♀️ So whenever Adam Feuerstein shares his astute insights, uneducated shareholders attack Mr. Feuerstein 🙇🏻‍♀️ https://stocktwits.com/ForestFoxes/message/635114203 #StatNews #AdamFeuerstein
0 · Reply
ForestFoxes
ForestFoxes Nov. 14 at 8:23 AM
$ANVS 📚8.4 🔦 👀 Insights ... from a shareholder with hundreds of interactions (email, phone, video ...) covering a vast number of topics, including: broken contracts, poached employee(s), abused contractors. Q: "I never give non-public information" then, why does Dr. Maccecchini's own attorneys tell her to "shut up!" Yes, attorneyS (plural) 🤐 👉 "The lawyers have told me to shut up ..." A: It's not because Dr. Maccecchini tells the truth. Note: On some topics Dr. Maccecchini controverts herself saying one thing on one email, then ... later saying the exact opposite thing. If one's own emails controvert each other does that make a person a liar? #goteamfox #parkinsons #research #FindACure#StatNews #adamfeuerstein #nih #nia #sec #RussoPartners #NicJohnson #TonyRusso
0 · Reply
ForestFoxes
ForestFoxes Nov. 14 at 7:46 AM
$ANVS 📚8.3 🔦 👀 Insights ... from a shareholder with hundreds of interactions (email, phone, video ...) with a vast number of topics, including: legal counsel. #GoTeamFox #Parkinsons #Research #FindACure#StatNews #AdamFeuerstein #NIH #NIA #SEC
0 · Reply
ForestFoxes
ForestFoxes Nov. 14 at 7:01 AM
$ANVS 📚8.2 🔦 👀 Insights ... "Elements of Truth" 21:53 - If we wanna become more accurate, we should capitalize on the wisdom of the crowd by listening more to others. [I've learned a lot from all of you. Thank you.] 21:59 In particular, we should listen to people who disagree with us. Understanding the best arguments of your critics, understanding what information those who disagree with you have that you lack is very helpful for making better decisions. [I don't understand why I'm being attacked, sometimes in very personal ways, when I am sharing facts.] 22:11 - The best calibrated people aren't those who know the most. It's those who know what they don't know. So, true wisdom lies not in being certain, but in knowing the limits of your own certainty. [I am certain of some things based on facts. The fact the SEC violations have occurred does NOT mean that the SEC will do anything about it. The fact that a large number of wrong doings has and is occurring doesn't mean that anyone cares. The fact that Dr. Maccecchini knowingly tells ... <insert word here, as IDK if the word "lies" is a legally proper term> ... Why are you so focuses on protecting CEOs, when it's patients that need to be protected??? https://www.youtube.com/watch?v=9M_QK4stCJU&t=181s #CFODive #MauraWebberSadovi #StatNews #AdamFeuerstein #StephenSedgwickCNBC #ENDALZ #FDA_Drug_Info #GoTeamFox #Parkinsons #Research #FindACure #UnityWalk #OutrunPD #NIH #NIA #SEC
0 · Reply
moneyonthebrain
moneyonthebrain Nov. 13 at 6:43 PM
$ANVS We got a nice bump in share price this week, but I think we'll get another if AVXL gets recommended for approval in Europe tomorrow - phase 2 ANVS data shows buntanetap outperforming AVXL's blarcamesine, so success for AVXL should rub off here...
1 · Reply
RockDoctor
RockDoctor Nov. 13 at 5:57 PM
$ANVS my point being, if not failed, holy mother
0 · Reply
RockDoctor
RockDoctor Nov. 13 at 5:55 PM
$ANVS is rock bottom at 3, 2, and 1. don't matter. it's priced as a failed company.
0 · Reply
TCNJ
TCNJ Nov. 13 at 5:15 PM
$ANVS Does the six month readout require all 760 patients complete a minimum of six months of dosing? Does that suggest full enrollment in the early spring?
3 · Reply
ReturnOfEsquire
ReturnOfEsquire Nov. 13 at 4:36 PM
$ANVS Knowing what I know now, I would hate to be sunk cost and P3 on a neurodegeneratve disease more than any other indication.
1 · Reply
macca456
macca456 Nov. 13 at 1:12 PM
$ANVS seems to Be renting 2/3$ for so long now it must seriously attract the day traders 94% down my self hope to even check out evens but so so long way of we can only hope and prey this delivers now
0 · Reply
nhyujm6
nhyujm6 Nov. 13 at 7:58 AM
$ANVS - See below - the "broader approach to treatment" validates ANVS approach - Japanese researchers found that lecanemab, an amyloid-clearing drug for Alzheimer’s, does not improve the brain’s waste clearance system in the short term. This implies that nerve damage and impaired clearance occur early and are difficult to reverse. Their findings underscore that tackling amyloid alone may not be enough to restore brain function, urging a broader approach to treatment.
0 · Reply